Sector revisions Scholar Rock Holding Corporation

Stocks

Market Closed - Nasdaq 23:00:00 04/09/2026 +03			5-day change	1st Jan Change
55.33 ^USD	-1.09%		-2.59%	+25.61%

09-02	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial	CI
09-02	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	SCHOLAR ROCK HOLDING CORPORATION							16
	WUXI APPTEC CO., LTD.							18
	ARGENX SE							15
	INSMED INCORPORATED							22
	BIONTECH SE							20
	WUXI BIOLOGICS (CAYMAN) INC.							24
	GENMAB A/S							15
	PHARMAESSENTIA CORPORATION							8
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							18
	EXELIXIS, INC.							16
	SUMMIT THERAPEUTICS INC.							13
	MADRIGAL PHARMACEUTICALS, INC.							16
	ARROWHEAD PHARMACEUTICALS, INC.							11
	AKESO, INC.							21
	CYTOKINETICS, INCORPORATED							20
	VAXCYTE, INC.							9
	REMEGEN CO., LTD.							16
	IMMUNITYBIO, INC.							4
	BELITE BIO, INC							9
	Average							15
	Weighted average by Cap.							17

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!